

2019

CONSORT Checklist, Myopia Outcome Study of Atropine in Children (MOSAIC): Design and Methodology

Saoirse McCrann

Technological University Dublin, mccrannsaoirse@gmail.com

Ian Flitcroft

Children's University Hospital, Temple Street, Dublin, Ireland, ian.flitcroft@dit.ie

John Butler

Technological University Dublin, john.s.butler@tudublin.ie

See next page for additional authors

Follow this and additional works at: <https://arrow.tudublin.ie/ceyerart>



Part of the [Optometry Commons](#), and the [Public Health Commons](#)

Recommended Citation

McCrann et al (2019) Checklist, Myopia Outcome Study of Atropine in Children (MOSAIC): Design and Methodology, doi.org/10.21427/3neg-gr77

This Other is brought to you for free and open access by the Centre for Eye Research Ireland at ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie.



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 4.0 License](#)

Authors

Saoirse McCrann, Ian Flitcroft, John Butler, and James Loughman



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Myopia Outcome Study of Atropine in Children (MOSAIC): Design and Methodology

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3-4
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5-7
	2b	Specific objectives or hypotheses	7
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	8, Figure 2
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	17,19
	4b	Settings and locations where the data were collected	8
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	11,12
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9,10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	
Sample size	7a	How sample size was determined	16
	7b	When applicable, explanation of any interim analyses and stopping guidelines	13
Randomisation:			11-12
Sequence generation	8a	Method used to generate the random allocation sequence	
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	11-12
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	11-12
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to	11-12

		interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	12-13
	11b	If relevant, description of the similarity of interventions	12
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	27-29
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	27-29
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	10 Figure 2
	13b	For each group, losses and exclusions after randomisation, together with reasons	
Recruitment	14a	Dates defining the periods of recruitment and follow-up	19-20
	14b	Why the trial ended or was stopped	
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
Other information			
Registration	23	Registration number and name of trial registry	8
Protocol	24	Where the full trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	7 Figure 1

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.